{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:08:28Z","timestamp":1789600108945,"version":"build-2803163510"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"13","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemolytic disease of the fetus and newborn (HDFN) is a rare and serious immune-mediated condition that can result in poor fetal and neonatal outcomes. During pregnancy, monitoring with middle cerebral artery Doppler ultrasound and intrauterine transfusions (IUTs) are the current standard of care, although intravenous immunoglobulin (IVIg) has been adopted in some centers to attempt to delay the onset of fetal anemia. Significant gaps remain in understanding the safety and effectiveness of current HDFN management, both during pregnancy and in neonates and children. We present the design of the Global Prospective Hemolytic Disease of the Fetus and Newborn Registry (GERANIUM; ClinicalTrials.gov Identifier: NCT07194070), a study that will provide real-world, prospective, longitudinal data on management, clinical course, and outcomes of HDFN from the antenatal period up to 2 years after birth.<\/jats:p>\n                  <jats:p>GERANIUM is a prospective, observational study enrolling alloimmunized pregnant individuals (aged \u226518 years) before 24 weeks of gestational age who are at high risk for HDFN based on previous obstetric history. This study will enroll approximately 175 participants across multiple global sites. Data collected during pregnancy include fetal loss, frequency and severity of HDFN, treatment patterns, as well as effectiveness and adverse outcomes of IUTs and other interventions. Following birth, infants will be followed for the first 2 years of life, with documentation of HDFN sequelae, including treatments, growth, and development. Impact on the parents and children will be assessed using validated participant- and observer-reported outcome measures.<\/jats:p>\n                  <jats:p>The GERANIUM registry will provide prospective, contemporaneous data on current management of HDFN and associated outcomes.<\/jats:p>","DOI":"10.1055\/a-2816-3361","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:14:59Z","timestamp":1774055699000},"page":"1731-1738","source":"Crossref","is-referenced-by-count":2,"title":["Study Design of the Global Prospective Hemolytic Disease of the Fetus and Newborn Registry (GERANIUM)"],"prefix":"10.1055","volume":"43","author":[{"given":"May Lee","family":"Tjoa","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Cambridge, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Orillion","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Mankoski","sequence":"additional","affiliation":[{"name":"The NemetzGroup, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Imran","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Mao","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Krumme","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Van Hoorde","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Linares-Rivas Rico","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12884-022-05329-z","article-title":"Hemolytic disease of the fetus and newborn: Systematic literature review of the antenatal landscape","volume":"23","author":"D P de Winter","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"100203","DOI":"10.1016\/j.xagr.2023.100203","article-title":"Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010","volume":"3","author":"D Yu","year":"2023","journal-title":"AJOG Glob Rep"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1186\/s12884-024-07044-3","article-title":"Hemolytic disease of the fetus and newborn and Rhesus alloimmunization in Latin American countries: a scoping review","volume":"24","author":"M D Corr\u00eaa Jr.","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00431-022-04724-0","article-title":"History and current standard of postnatal management in hemolytic disease of the fetus and newborn","volume":"182","author":"D P De Winter","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17474086.2017.1331124","article-title":"Neonatal management and outcome in alloimmune hemolytic disease","volume":"10","author":"I MC Ree","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/j.1537-2995.2008.01742.x","article-title":"One single dose of 200 \u03bcg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy","volume":"48","author":"J M Koelewijn","year":"2008","journal-title":"Transfusion"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"e70085","DOI":"10.1002\/pmf2.70085","article-title":"Red blood cell alloimmunization and pregnancy: diagnosis and management","volume":"1","author":"B Valentini","year":"2025","journal-title":"Pregnancy"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/1471-0528.17674","article-title":"Severity of haemolytic disease of the fetus and newborn in patients with a history of intrauterine transfusions in a previous pregnancy: a nationwide retrospective cohort study","volume":"131","author":"R M van't Oever","year":"2024","journal-title":"BJOG"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/trf.15635","article-title":"Rhesus D alloimmunization in pregnancy from 1996 to 2015 in Iceland: a nation-wide population study prior to routine antenatal anti-D prophylaxis","volume":"60","author":"B Gudlaugsson","year":"2020","journal-title":"Transfusion"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00404-007-0446-x","article-title":"Relationship between obstetric history and Rh(D) alloimmunization severity","volume":"277","author":"G Lobato","year":"2008","journal-title":"Arch Gynecol Obstet"},{"issue":"08","key":"ref12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/vox.13651","article-title":"Disease severity in subsequent pregnancies with RhD immunization: a nationwide cohort","volume":"119","author":"C Zwiers","year":"2024","journal-title":"Vox Sang"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"e2023064604","DOI":"10.1542\/peds.2023-064604","article-title":"Neonatal and obstetrical outcomes of pregnancies complicated by alloimmunization","volume":"153","author":"T M Bahr","year":"2024","journal-title":"Pediatrics"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1016\/S2352-3026(24)00314-4","article-title":"Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study","volume":"11","author":"D P de Winter","year":"2024","journal-title":"Lancet Haematol"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.xagr.2025.100544","article-title":"Clinical characteristics and outcomes of pregnancies at-risk of hemolytic disease of the fetus and newborn in Sweden, Finland, and Denmark: a population-based register study","volume":"5","author":"K HM Kwok","year":"2025","journal-title":"AJOG Glob Rep"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/aogs.12590","article-title":"Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study","volume":"94","author":"S Sainio","year":"2015","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1186\/s12884-023-06061-y","article-title":"Hemolytic disease of the fetus and newborn: Rapid review of postnatal care and outcomes","volume":"23","author":"D P de Winter","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"e2454330","DOI":"10.1001\/jamanetworkopen.2024.54330","article-title":"Variations and opportunities in postnatal management of hemolytic disease of the fetus and newborn","volume":"8","author":"D P de Winter","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3109\/14767058.2011.633668","article-title":"Predictive factors of perinatal mortality in transfused fetuses due to maternal alloimmunization: What really matters?","volume":"25","author":"G C Osanan","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ajog.2015.01.059","article-title":"Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: The fetus at risk for anemia\u2013diagnosis and management","volume":"212","author":"G Mari","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ajog.2024.11.003","article-title":"Monitoring and management of hemolytic disease of the fetus and newborn based on an international expert Delphi consensus","volume":"232","author":"H J Mustafa","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1157004","DOI":"10.3389\/fped.2023.1157004","article-title":"Fetal and neonatal outcome in severe alloimmunization managed with intrauterine transfusion: 18-year experience in a tertiary referral hospital in China","volume":"11","author":"W Pan","year":"2023","journal-title":"Front Pediatr"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1111\/aogs.14261","article-title":"Management and clinical consequences of red blood cell antibodies in pregnancy: a population-based cohort study","volume":"100","author":"S Liu","year":"2021","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/uog.17319","article-title":"Complications of intrauterine intravascular blood transfusion: Lessons learned after 1678 procedures","volume":"50","author":"C Zwiers","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"291.e1","DOI":"10.1016\/j.ajog.2018.06.007","article-title":"Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn","volume":"219","author":"C Zwiers","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/trf.14453","article-title":"Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion","volume":"58","author":"L C Nwogu","year":"2018","journal-title":"Transfusion"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ajog.2024.03.044","article-title":"Intravenous immunoglobulin for the treatment of severe maternal alloimmunization: Individual patient data meta-analysis","volume":"231","author":"H J Mustafa","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"138.e1","DOI":"10.1016\/j.ajog.2006.10.890","article-title":"Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization","volume":"196","author":"M S Ruma","year":"2007","journal-title":"Am J Obstet Gynecol"},{"issue":"07","key":"ref29","doi-asserted-by":"crossref","first-page":"102119","DOI":"10.1016\/j.jogoh.2021.102119","article-title":"Effect of intravenous immunoglobulins to postpone the gestational age of first intrauterine transfusion in very severe red blood cell alloimmunization: a case-control study","volume":"50","author":"E Maisonneuve","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"07","key":"ref30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/a-2404-8089","article-title":"Design of a phase 3, global, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn","volume":"42","author":"Y Komatsu","year":"2025","journal-title":"Am J Perinatol"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/uog.7696","article-title":"Early intrauterine transfusion in severe red blood cell alloimmunization","volume":"36","author":"Y Yinon","year":"2010","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12884-025-07208-9","article-title":"Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review","volume":"25","author":"P Maurice","year":"2025","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2816-3361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:41:40Z","timestamp":1789598500000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2816-3361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":31,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,9,16]]},"published-print":{"date-parts":[[2026,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2816-3361","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}